Singapore Markets closed

Novartis AG (NVSEF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
82.740.00 (0.00%)
At close: 01:03PM EDT
Full screen
Loading interactive chart…
  • Zacks

    Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets

    The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.

  • The Guardian

    Novartis scraps cholesterol drug trial in blow to UK life sciences ambitions

    Swiss firm’s withdrawal from Leqvio trial with NHS dents government plans to attract post-Brexit research and investment

  • Financial Times

    Novartis scraps drug trial in blow to UK life sciences ambitions

    A Swiss pharmaceutical group has scrapped plans to conduct a major drug trial in the UK, damaging government efforts to showcase the country as an attractive destination for investment in life sciences after Brexit. Three years ago Novartis’s decision to collaborate with the NHS on rolling out inclisiran, a twice-yearly injectable drug for lowering cholesterol, was announced to fanfare, after the UK’s slow take-up of innovative medicines compared with peers was criticised. Matt Hancock, health secretary at the time, described it as “a strong vote of confidence in our world-leading life sciences sector”.